FDA concurs with EMA's diabetes drug conclusions

08/1/2013 | Medical Marketing & Media

The FDA said it agrees with the conclusions of the European Medicines Agency's Committee for Medicinal Products for Human Use that rejected a link between a class of diabetes drugs called incretin mimetics and increased risk of pancreatic adverse events including pancreatic cancer. "Our general view is that their conclusions are consistent with our current understanding of the data," the FDA's Center for Drug Evaluation and Research said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC